Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Phase 3 trialsStub

Cagrilintide

Long-acting amylin analogue

A long-acting analogue of the hormone amylin, studied alone and together with semaglutide in phase 3 trials in obesity.

Reconstitution calculator

At a glance

Phase 3 trials

Large randomized trials in people are running or published. It is not a licensed medicine.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3: Cagrilintide

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

106
papers on PubMed
64
of them in people
15
randomized trials
50
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Cagrilintide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Cagrilintide; no amount here is a recommendation.

Cagrilintide: on PubMed

What PubMed held for Cagrilintide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

106
papers
64
in humans
15
clinical trials
15
randomized trials
2012: 0 papers122013: 0 papers2014: 0 papers142015: 0 papers2016: 0 papers162017: 0 papers2018: 0 papers182019: 0 papers2020: 0 papers202021: 8 papers2022: 6 papers222023: 5 papers2024: 14 papers242025: 30 papers2026: 51 papers so far26
Papers per year, 2012 to 2026. The most in one year: 51.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

    ReviewYao H, Zhang A, Li D, et al. BMJ (Clinical research ed.), 2024. PMID 38286487

  2. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

    ReviewNong K, Shi Q, Xie X, et al. BMJ (Clinical research ed.), 2026. PMID 42419792

  3. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

    Randomized trialGarvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine, 2025. PMID 40544433

  4. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Randomized trialDavies MJ, Bajaj HS, Broholm C, et al. The New England journal of medicine, 2025. PMID 40544432

  5. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

    Randomized trialFrias JP, Deenadayalan S, Erichsen L, et al. Lancet (London, England), 2023. PMID 37364590

  6. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

    Randomized trialLau DCW, Erichsen L, Francisco AM, et al. Lancet (London, England), 2021. PMID 34798060

  7. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis

    ReviewDutta D, Nagendra L, Harish BG, et al. Indian journal of endocrinology and metabolism, 2024. PMID 39676787

  8. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

    StudyD'Ascanio AM, Mullally JA, Frishman WH Cardiology in review, 2024. PMID 36883831

Search used: ("Cagrilintide"[tiab]). Run it on PubMed

Research links

Also in Metabolic

Sold in blends: Cagrilintide + Semaglutide, Retatrutide + Cagrilintide